Emily is a former editorial intern at Spectrum and a graduate student in New York University’s Science, Health & Environmental Reporting Program. Previously, Emily worked on aging research in Boston, Massachusetts. She has a B.A. in chemistry from Williams College in Williamstown, Massachusetts.
Emily Harris
Former news intern
Spectrum
From this contributor
Prenatal exposures; Angelman trial suspension; autistic adult well-being
This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.
Prenatal exposures; Angelman trial suspension; autistic adult well-being
By
Emily Harris
17 July 2023 | 4 min read
Null and Noteworthy: Modified MRI; father findings
This month’s newsletter tackles null findings from an attempted replication of a “revolutionary” MRI approach and an analysis of family genetics.
Null and Noteworthy: Modified MRI; father findings
By
Emily Harris
22 June 2023 | 4 min read
Null and Noteworthy: Reinforcing rigor; medication medley
This month’s newsletter highlights findings on the use of three medication types during pregnancy.
Null and Noteworthy: Reinforcing rigor; medication medley
By
Emily Harris
14 December 2022 | 4 min read
Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.
Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
By
Emily Harris
10 November 2022 | 5 min read
Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness
Parents’ health, treatment dosages and sensory perception feature in this month’s crop of null and replicated results.
Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness
By
Emily Harris
13 October 2022 | 5 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read